Wyeth
Also known as: clinicaltrialinfo@wyeth.com | For Argentina, Chile, scheima@wyeth.com | For Argentina, Chile, scheima@wyeth.com, rendop@wyeth.com | For Argentina, Scheima@wyeth.com | For Argentina: Scheima@wyeth.com | For Argentina, scheima@wyeth.com or rendop@wyeth.com | For Australia and Hong Kong, medinfo@wyeth.com | For Australia, China, Hong Kong, medinfo@wyeth.com | For Australia, Korea, Taiwan, medinfo@wyeth.com | For Australia, medinfo@wyeth.com | For Australia, New Zealand, medinfo@wyeth.com | For Australia, Taiwan, medinfo@wyeth.com | For Austria, medinfo@wyeth.com | For Austria, WPVIMED@wyeth.com | For Belgium, trials-BEL@wyeth.com | For Belguim, trials-BEL@wyeth.com | For Brazil, xavierl@wyeth.com | For Canada, clintrialparticipation@wyeth.com | For Chile, scheima@wyeth.com | For Chile: scheima@wyeth.com | For China, medinfo@wyeth.com | For China: medinfo@wyeth.com | For Croatia, WPBUMED@wyeth.com | For Czech Republic, WPPGCLI@wyeth.com | For Denmark, Finland, MedInfoNord@wyeth.com | For Denmark, Finland, Norway, and Sweden, medinfonord@wyeth.com | For Denmark, Finland, Sweden, MedInfoNord@wyeth.com | For Denmark, Finland, Sweden, Norway, MedInfoNord@wyeth.com | For Denmark, medinfonord@wyeth.com | For Drug Consulting | For Estonia, Latvia, Lithuania, WPVIMED@wyeth.com | For Estonia, WVPMED@wyeth.com | For Finland, MedInfoNord@wyeth.com | For Finland, Sweden, MedInfoNord@wyeth.com | For France, infomedfrance@wyeth.com | For France: infomedfrance@wyeth.com | For Germany, medinfoDEU@wyeth.com | For Germany, MedinfoDEU@wyeth.com | For Germany, MedInfoDEU@wyeth.com | For Greece, decresg@wyeth.com | For Hong Kong, medinfo@wyeth.com | For Hong Kong: medinfo@wyeth.com | For Hungary, Croatia, WPBUMED@wyeth.com | For Hungary, WPBUMED@wyeth.com | For Hungary: WPBUMED@wyeth.com | For Ireland, ukmedinfo@wyeth.com | For Italy, decresg@wyeth.com | For Italy, descresg@wyeth.com | For Italy, Greece, decresg@wyeth.com | For Italy,Greece, decresg@wyeth.com | For Latvia, WPVIMED@wyeth.com | For Lithuania, WPVIMED@wyeth.com | For Mexico, gomezlj@wyeth.com | For Mexico, gomezzlj@wyeth.com | For Mexico: gomezzlj@wyeth.com | For Netherlands, trials-NL@wyeth.com | For New Zealand, medinfo@wyeth.com | For Norway, Finland, MedInfoNord@wyeth.com | For Norway, Sweden, MedInfoNord@wyeth.com | For Poland, WPWZMED@wyeth.com | For Poland: WPWZMED@wyeth.com | For Poland, WVWZMED@wyeth.com | For Portugal,Saudi Arabia, clintrialparticipation@wyeth.com | For Romania and Russia, WPVIMED@wyeth.com | For Romania, WPVIMED@wyeth.com | For Romania, WVPIMED@wyeth.com | For Russia, WVPIMED@wyeth.com | For Serbia, WPVIMED@wyeth.com | For Slovakia, DIS-WP-BV-EUBV01-Medical@wyeth.com | For South Africa, AZFinfo@wyeth.com | For South Africa, please contact ZAFinfo@wyeth.com | For South Africa, ZAFinfo@wyeth.com | For South Africa: ZAFinfo@wyeth.com | For Spain, infomed@wyeth.com | For Spain: infomed@wyeth.com | For Spain, Italy, Portugal, the Netherlands, and Finland, clinicaltrialinfo@wyeth.com | For Sweden and Denmark, MedInfoNord@wyeth.com | For Sweden, Denmark and Norway, MedInfoNord@wyeth.com | For Sweden, Finland,MedInfoNord@wyeth.com | For Sweden, MedInfoNord@wyeth.com | For Sweden: MedInfoNord@wyeth.com | For Switzerland, med@wyeth.com | For Taiwan, medinfo@wyeth.com | For Taiwan: medinfo@wyeth.com | For Turkey, Erisc@wyeth.com | For UK/Great Britian, ukmedinfo@wyeth.com | For UK/Great Britian: ukmedinfo@wyeth.com | For Ukraine, Romania, WPVIMED@wyeth.com | For Ukraine, WVPIMED@wyeth.com | For UK, ukmedinfo@wyeth.com | For UK, ukmedonfo@wyeth.com | For United Kingdom and Ireland, ukmedinfo@wyeth.com | For United Kingdom, ukmedinfo@wyeth.com | Wyeth | WYETH CONS | Wyeth-Lederle Vaccines | Wyeth Pharmaceuticals Inc. | Wyeth Pharmaceuticals LLC | WYETH PHARMS | WYETH PHARMS INC | Wyeth Reseach | Wyeth Reserach
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1992First marketed drug
May 8, 1942First NDA
Oct 28, 1953Last known activity
Oct 11, 2022
Timeline
1860s
- Jul 1, 1860
Wyeth— Founded
1930s
- Jan 1, 1931
American Home Products— Acquired By
1950s
- Aug 23, 1957
brompheniramine maleate— NDA Organization
1960s
- Apr 30, 1965
ethionamide— NDA Secondary Org
1990s
- Dec 30, 1994
medroxyprogesterone— Marketing Organization
2000s
- Oct 15, 2009
Pfizer— Now
Drugs by trial phase (187 distinct, 513 trials)
Phase 4 (46 own, 0 via acquisition)
Phase 3 (49 own, 0 via acquisition)
Phase 2 (34 own, 0 via acquisition)
Phase 1 (53 own, 0 via acquisition)
Other trials (5 own, 0 via acquisition)
Indications
Approved for
- Acute Pain
- Amenorrhea
- Anxiety
- Arthritis, Rheumatoid
- Bacterial Infections
- Bronchitis
- Common Cold
- Esotropia
- Gastric Acidity Determination
- Glaucoma, Open-Angle
- Hypertension
- Hypogonadism
- Infections
- Intraabdominal Infections
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Major Depressive Disorder
- Mycoses
- Neuroblastoma
- Organophosphate Poisoning
- Osteoarthritis
- Pain
- Pelvic Infection
- Pneumonia
- Pneumonia, Bacterial
- Pneumonia, Ventilator-Associated
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Psychomotor Agitation
- Pyelonephritis
- Schizophrenia
- Skin Diseases, Infectious
- Staphylococcal Infections
- Staphylococcal Skin Infections
- Tachycardia, Ventricular
- Urinary Tract Infections
- Ventricular Fibrillation
Studied for
- Abdominal Abscess
- Abscess
- Acalculous Cholecystitis
- Adenocarcinoma
- Alzheimer Disease
- Anemia, Sickle Cell
- Anxiety Disorders
- Apnea
- Appendicitis
- Arrhythmias, Cardiac
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Atrial Fibrillation
- Atrophic Vaginitis
- Atrophy
- Bacterial Infections
- Bipolar Disorder
- Body Weight
- Body Weight Changes
- Brain Neoplasms
- Breast Neoplasms
- Breast Neoplasms, Male
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Islet Cell
- Carcinoma, Medullary
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Cardiovascular Diseases
- Carotid Body Tumor
- Central Nervous System Neoplasms
- Cholecystitis
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Community-Acquired Infections
- Constipation
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Cross Infection
- Delayed Graft Function
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Foot
- Diabetic Nephropathies
- Diabetic Neuropathies
- Disease
- Diverticulitis
- Dysmenorrhea
- Dyspareunia
- Emergencies
- Endometrial Hyperplasia
- Endometrial Neoplasms
- Endometriosis
- Enthesopathy
- Esophageal Diseases
- Esophagitis
- Esophagitis, Peptic
- Fallopian Tube Neoplasms
- Fever
- Fibromyalgia
- Fibrosis
- Fractures, Bone
- Fractures, Closed
- Gastroesophageal Reflux
- Gastrointestinal Neoplasms
- Genital Neoplasms, Female
- Germinoma
- Glioblastoma
- Glomerulonephritis
- Glomerulonephritis, IGA
- Glomerulonephritis, Membranous
- Glucose Intolerance
- Glucose Metabolism Disorders
- Graft vs Host Disease
- Gram-Negative Bacterial Infections
- Gram-Positive Bacterial Infections
- Heartburn
- Heart Diseases
- Hematologic Neoplasms
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Hepatic Insufficiency
- Hepatitis
- Hepatitis C
- HIV Infections
- Hodgkin Disease
Marketed drugs (42)
Recent trials (50)
- NCT05468073CollaboratorPhase 2Oct 11, 2022
- NCT03576417CollaboratorPhase 3Jul 31, 2018
- NCT02957760CollaboratorPhase 2Dec 1, 2015
- NCT01680250CollaboratorPhase 2/Phase 3Sep 1, 2011
- NCT01068353CollaboratorPhase 2Jan 1, 2011
- NCT01360372CollaboratorPhase 3Oct 1, 2010
- NCT00931957CollaboratorN/AOct 1, 2010
- NCT01235442CollaboratorPhase 3Sep 1, 2010
- NCT01050985CollaboratorPhase 1Jul 1, 2010
- NCT01134575CollaboratorPhase 1Jun 1, 2010
- NCT01155258CollaboratorPhase 1Jun 1, 2010
- NCT01170052CollaboratorPhase 1/Phase 2May 1, 2010
- NCT01111448CollaboratorPhase 2Apr 1, 2010
- NCT00997360Study directorPhase 1Feb 1, 2010
- NCT01567930CollaboratorPhase 2Feb 1, 2010
Details
- Founded
- Philadelphia, PA, US Jul 1, 1860
- First NDA
- Oct 28, 1953
- Last known activity
- Oct 11, 2022
Designations held
- Orphan drug
- Fast track
- Priority review